During the early 2016/17 influenza season, influenza A(H3N2) was the main circulating virus in Europe \[[@r1]\]. Although most of the A(H3N2) viruses characterised genetically matched the vaccine component, a high incidence of severe cases was detected \[[@r1],[@r2]\]. We present the 2016/17 mid-season vaccine effectiveness (VE) estimates in preventing laboratory-confirmed influenza A(H3N2), relative to different combinations of current and prior seasonal influenza vaccinations.

Setting and information sources
===============================

In the 2016/17 season the A(H3N2) component recommended for the influenza vaccine in the northern hemisphere was A/HongKong/4801/2014-like virus (group 3C.2a) \[[@r3]\], in the 2015/16 season A/Switzerland/9715293/2013-like (group 3C.3a) \[[@r4]\], and in seasons 2012/13 to 2014/15 it was A/Texas/50/2012-like or A/Victoria/361/2011-like (group 3C.1) \[[@r5]\].

The Influenza Surveillance System in Spain reported that as of 9 February 2017, 99% of the sentinel detections of influenza virus were A(H3N2), and sequence analysis of the HA1 fragment of the haemagglutinin gene found 74% of strains as A/Bolzano/7/2016 (group 3C.2a1) and 21% as A/HongKong/4801/2014, both of which matched the vaccine component \[[@r2]\].

A test-negative case--control study was conducted, based on epidemiological and virological surveillance of influenza in primary healthcare and hospitals in Navarre, northern Spain. The influenza vaccination campaign took place in October and November 2016. The trivalent inactivated non-adjuvanted vaccine was offered free of charge to a target group for vaccination, including people aged 60 years or over and those with major chronic conditions (body mass index ≥40 kg/m^2^, cancer, liver cirrhosis, dementia, diabetes mellitus, immunodeficiency, heart disease, renal disease, respiratory disease, rheumatic disease, and stroke).

Influenza vaccine status in seasons 2012/13 to 2016/17 was obtained from the online regional vaccination register \[[@r6]\]. These five seasons were considered because for all of them the A(H3N2) component included in the vaccine belonged to clade 3C \[[@r3]-[@r5]\].

Patients were considered to be protected from influenza 14 days after vaccine administration in the current season.

Influenza surveillance was based on automatic reporting of cases of influenza-like illness (ILI) from all primary healthcare physicians and hospitals \[[@r7]\]. A sentinel network of primary healthcare physicians was requested to take nasopharyngeal and pharyngeal swabs from their patients diagnosed with ILI, whose symptoms had begun less than five days previously. In hospitals, the protocol specified early detection and swabbing of all hospitalised patients with ILI. Samples were processed by reverse transcription-polymerase chain reaction assay.

Statistical analysis
====================

The study population included persons covered by the Navarre Health Service since 2012 (96% of the population). All patients who were swabbed between 1 December 2016 (beginning of continued detection of influenza virus) and 31 January 2017 were initially considered. Healthcare workers, persons living in nursing homes, children less than 9 years-old and patients hospitalised before ILI symptom onset were excluded. We compared seasonal vaccination status in patients for whom A(H3N2) influenza virus was detected (cases) and in those who were negative for influenza (controls). Crude and adjusted odds ratios (OR) with their 95% confidence intervals (CI) were calculated using logistic regression models. Adjusted models included sex, age group (9--24, 25--44, 45--64, 65--84 and ≥ 85 years), major chronic conditions, month of swabbing, and healthcare setting (primary healthcare and hospital). Six categories combining current vaccination status with vaccination in the four prior seasons and thus distinguishing between frequent and infrequent vaccinees were considered \[[@r8],[@r9]\]: current-season vaccination and \> 2 prior doses, current-season vaccination and 1--2 prior doses, current-season vaccination and no prior doses, no current-season vaccination and \> 2 prior doses, no current-season vaccination and 1--2 prior doses, and no current-season vaccination and no prior doses (reference group). To compare VE among categories, the model was repeated using the category with current season vaccination and \> 2 prior doses as the reference. VE was estimated as a percentage: (1--OR) × 100.

Early estimation of influenza vaccine effectiveness
===================================================

Of 1,243 ILI initial patients, one case of non-subtyped influenza A and two influenza B cases were not further considered. The remaining 1,240 ILI patients were included in the study and consisted of 783 (63%) hospitalised patients and 457 primary healthcare patients. A total of 591 (48%) were confirmed cases for influenza A(H3N2) and were compared with 649 controls negative for any influenza virus.

Compared with test-negative controls, A(H3N2) influenza cases had a lower proportion of persons over 65 years-old (53% (315/591) in cases vs 62% (401/649) in controls; p = 0.003), with major chronic conditions (59% vs 71%; p \< 0.001; [Table 1](#t1){ref-type="table"}) and who were treated in hospital (51% (300/591) vs 74% (483/649; p \< 0.001)). Among the cases, 41% had received the 2016/17 seasonal vaccine, vs 50% of the controls (p = 0.001) ([Table 1](#t1){ref-type="table"}).

###### Characteristics, according to the healthcare setting and test result, of patients with medically-attended influenza-like illness included in the test-negative case--control analysis, Navarre, Spain, 1 December 2016--31 January 2017 (n = 1,240 patients)

  Characteristics                       All patients   Hospitalised patients   Primary healthcare patients                                                                                   
  ------------------------------------- -------------- ----------------------- ----------------------------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  **Age groups in years**                                                                                                                                                                    
  9--24                                 37             6                       56                            9         14        3         1         0         23        14        55        19
  25--44                                76             12                      99                            17        22        5         7         2         54        33        92        32
  45--64                                135            21                      121                           20        80        17        33        11        55        33        88        30
  65--84                                269            41                      197                           33        236       49        143       48        33        20        54        19
  ≥ 85                                  132            20                      118                           20        131       27        116       39        1         1         2         1
  **Sex**                                                                                                                                                                                    
  Male                                  331            51                      274                           46        269       56        151       50        62        37        123       42
  Female                                318            49                      317                           54        214       44        149       50        104       63        168       58
  **Residence**                                                                                                                                                                              
  Rural                                 237            37                      213                           36        213       44        154       51        24        15        59        20
  Urban                                 412            63                      378                           64        270       56        146       49        142       86        232       80
  **Major chronic conditions**                                                                                                                                                               
  No                                    189            29                      242                           41        78        16        43        14        111       67        199       68
  Yes                                   460            71                      349                           59        405       84        257       86        55        33        92        32
  **Month of swabbing**                                                                                                                                                                      
  December                              159            24                      139                           24        106       22        58        19        53        32        81        28
  January                               490            76                      452                           76        377       78        242       81        113       68        210       72
  **Target group for vaccination^a^**                                                                                                                                                        
  No                                    124            19                      182                           31        36        7         11        4         88        53        171       59
  Yes                                   525            81                      409                           69        447       93        289       96        78        47        120       41
  **2016/17 season vaccine**                                                                                                                                                                 
  No                                    327            50                      351                           59        205       42        113       38        122       73        238       82
  Yes                                   322            50                      240                           41        278       58        187       62        44        27        53        18
  **Total**                             **649**        **100**                 **591**                       **100**   **483**   **100**   **300**   **100**   **166**   **100**   **291**   **100**

^a^ Target group for vaccination includes people ≥ 60 years old and people with major chronic conditions (body mass index ≥40 kg/m^2^, cancer, liver cirrhosis, dementia, diabetes mellitus, immunodeficiency, heart disease, renal disease, respiratory disease, rheumatic disease and stroke).

The overall adjusted estimate of influenza VE was 15% (95%CI: --11 to 35). The estimates were similar in the analysis of the target group for vaccination (16%), and were somewhat better in persons younger than 65 years (24%) than in the older age group (≥ 65 years; 11%). The point estimates suggested higher VE in outpatients (48%; 95%CI: --1 to 65) than in inpatients (0%; 95%CI: --38 to 27) ([Table 2](#t2){ref-type="table"}).

###### Influenza vaccine effectiveness in preventing laboratory-confirmed influenza A(H3N2) among individuals ≥ 9 years-old in Navarre, Spain, 1 December 2016--31 January 2017 (n = 1,240 patients)

  -----------------------------------------------------------------------------------------------------------------------------
  Characteristics                   Controls\                 Cases\                       Crude VE   \       Adjusted VE   \
                                    Vaccinated/unvaccinated   Vaccinated/unvaccinated   % (95% CI)         % (95% CI)^a^
  --------------------------------- ------------------------- ------------------------- ------------------ --------------------
  **Both healthcare settings**                                                                             

  All swabbed patients              322/327                   240/351                   31 (13 to 45)      15 (−11 to 35)

  Target group for vaccination^b^   307/218                   225/184                   13 (−13 to 33)     16 (−12 to 37)

  Age group in years                                                                                       

  9−64                              56/192                    37/239                    47 (16 to 66)      24 (−26 to 55)

  ≥ 65                              266/135                   203/112                   8 (−25 to 33)      11 (−23 to 35)

  **Hospitalised patients**                                                                                

  All swabbed patients              278/205                   187/113                   −22 (−64 to 9)     0 (−38 to 27)

  Target group for vaccination^b^   272/175                   185/104                   −14 (−55 to 16)    2 (−36 to 29)

  Age group in years                                                                                       

  9−64                              33/83                     14/27                     −30 (−179 to 39)   −27 (−188 to 44)

  ≥ 65                              245/122                   173/86                    0 (−40 to 29)      5 (−34 to 33)

  **Primary healthcare patients**                                                                          

  All swabbed patients              44/122                    53/238                    38 (3 to 61)       48 (−1 to 65)

  Target group for vaccination^b^   35/43                     40/80                     39 (−10 to 66)     54 (10 to 77)

  Age group in years                                                                                       

  9−64                              23/109                    23/212                    49 (4 to 72)       43 (−8 to 70)

  ≥ 65                              21/13                     30/26                     29 (−70 to 70)     44 (−41 to 78)
  -----------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; VE: vaccine effectiveness.

**^a^** Logistic regression model adjusted for sex, age group (9--24, 25--44, 45--64, 65--85 and ≥ 85 years), major chronic conditions, month of swabbing and healthcare setting (primary healthcare and hospital).

^b^ Target group for vaccination includes people ≥ 60 years old and people with major chronic conditions (body mass index ≥40 kg/m^2^, cancer, liver cirrhosis, dementia, diabetes mellitus, immunodeficiency, heart disease, renal disease, respiratory disease, rheumatic disease and stroke).

In the pooled analysis of all patients, as compared with individuals unvaccinated in the current and four prior seasons, the preventive effect was 61% (95%CI: 30 to 78) in those vaccinated in the current season who had also received 1--2 doses of vaccine in the prior seasons, 24% (95% CI: --6 to 46) in those vaccinated in the current season after 3--4 doses, 42% (95% CI: --5 to 68) in those vaccinated only in the current season, 58% (95%CI: 26 to 78) in individuals without current vaccination but with \> 2 prior doses, and 44% (95% CI: 3 to 68) in those unvaccinated in the current season but with 1--2 prior doses. Current and 1--2 dose prior season vaccination, or current season non-vaccination in people with \> 2 prior doses showed statistically significant higher protection than current and \> 2 prior season vaccinations ([Figure](#f1){ref-type="fig"}).
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In separated analyses of outpatients and inpatients, vaccination only in the current season was protective for primary healthcare consultations but not for hospitalisations. In hospitalised patients however, a history of vaccination in the prior seasons appeared to confer enhanced protection, whether the inpatients were vaccinated or not in the current season ([Figure](#f1){ref-type="fig"}).

Discussion and conclusion
=========================

Estimates of VE during the influenza season help guide health interventions aimed at reducing the impact of influenza in the population \[[@r10]\] and may help in the selection of strains to be contained in the next season's vaccine. For the 2016/17 season in Navarre, when vaccination status in the prior influenza seasons was not considered, we found low VE (15%) in the whole pool of patients, null VE for hospitalised patients and better protection (48%) for outpatients; the higher protection level in outpatients is consistent with the early estimates reported from the Canadian Sentinel Practitioner Surveillance Network \[[@r11]\].

In the analysis considering vaccination history; however, better levels of protection were observed for many of the combinations of current and prior season vaccination, especially for hospitalised patients. The results of the overall analysis suggest that the protective effect of the influenza vaccination against A(H3N2) virus in Navarre in the early 2016/17 season ranged from 24% to 61%, depending on the vaccination status in the current and prior seasons.

The VE estimates were strongly related to the vaccination history. One or two vaccine doses over the four prior seasons maintained or increased the protection of the current season vaccination, but three or more prior doses had a negative interference with the current season vaccine effect. A similar interference was described in previous seasons by other authors \[[@r8],[@r12]\], and inverse exposure-response association has been reported between repeated influenza vaccination and haemagglutinin antibodies titres for A(H3N2) virus \[[@r13]\].

Our results obtained from two independently recruited groups, inpatients and outpatients, were broadly consistent. The main difference was that vaccination only in the current season was protective for influenza cases attended in primary healthcare but not against influenza hospitalisations, which may be due to the poorer immune response among patients that need hospitalisation. Especially remarkable is the preventive effect observed for the vaccine doses received in prior seasons in individuals without current season vaccination.

This study has some limitations. Natural immunity due to exposure to influenza virus was not considered; however, in a previous study we demonstrated that it was not a relevant confounding factor or effect modifier of influenza VE \[[@r7]\]. Since these results are preliminary and have limited statistical power for some analyses, the final results for the season may be different. The study compared laboratory-confirmed cases with controls recruited in the same settings before either patient or physician knew the laboratory result, an approach that reduced selection bias \[[@r14]\]. We included patients recruited in primary care and hospitals, thus achieving representation of the whole spectrum of patients with influenza. The healthcare setting could have acted as a confounding factor, therefore the analyses were adjusted for this variable. This study evaluates a particular situation of circulating virus and composition of the vaccines; caution should be taken in generalising its outcome.

In conclusion, the results suggest that, overall, the different combinations of vaccination in the current and prior seasons were moderately effective against influenza A(H3N2) in the early 2016/17 season in northern Spain. In spite of the possible interferences between the effects of the current season vaccine and frequent prior vaccination, these findings highlight the net benefit of immunisation against influenza.
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